Share This Page
Drug Price Trends for TESTIM
✉ Email this page to a colleague
Average Pharmacy Cost for TESTIM
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TESTIM 1% (50 MG) GEL | 66887-0001-05 | 3.77685 | GM | 2026-04-22 |
| TESTIM 1% (50 MG) GEL | 66887-0001-05 | 3.77591 | GM | 2026-03-18 |
| TESTIM 1% (50 MG) GEL | 66887-0001-05 | 3.77752 | GM | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
TESTIM Market Analysis and Financial Projection
What is TESTIM?
TESTIM (testosterone in gel form) is a prescription medication used for testosterone replacement therapy (TRT). It is primarily prescribed for males diagnosed with hypogonadism or testosterone deficiency. TESTIM is formulated as a topical gel, applied daily to the skin. The product received FDA approval in 2002 and is marketed by Endo Pharmaceuticals.
How is the TESTIM Market Structured?
The global testosterone therapy market is segmented by product type, formulation, and geography. Within topical testosterone, TESTIM faces competition from other gels (e.g., AndroGel, Axiron, Fortesta), patches, injections, and pellets.
Key market segments include:
- Product Type: Topical gels (TESTIM, AndroGel), patches, injections.
- Geography: North America, Europe, Asia-Pacific.
- End-user: Hospitals, clinics, home use.
What are the Current Market Dynamics?
Market Size and Trends
The global testosterone therapy market was valued at approximately USD 1.4 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 4-6% through 2030. North America accounts for 60-65% of sales, driven by high awareness, reimbursement policies, and aging male populations.
Competitive Position of TESTIM
Immediate competitors in topical testosterone include:
- AndroGel (AbbVie): Market leader, slightly more widely adopted.
- Axiron (Eli Lilly): Patches.
- Fortesta (Endo Pharmaceuticals): Gel, similar to TESTIM.
TESTIM's market share has declined slightly over recent years due to increased competition and patent expirations. Its position remains solid, especially in markets with established distribution channels.
Patent and Regulatory Status
Most primary patents have expired around 2018-2020, leading to generic formulations entering the market. Endo's exclusivity was extended through formulation patents, but patent challenges are ongoing.
Pricing Models
TESTIM is priced at USD 600-750 per 30-gram tube in the U.S. depending on pharmacy and insurance coverage. Generic versions price below USD 400 for similar quantities, pressuring brand pricing.
Reimbursement and Adoption
High insurance coverage in the U.S. supports access, but cost remains a barrier for some patients. European markets have variable reimbursement policies, affecting market penetration.
What Are the Price Projections?
Short-term (2023-2025)
- Price Stability: Expect a gradual decline in brand-name prices by 5-8%, driven by patent expiries and increased generic competition.
- Retail Price Range: USD 600-750 per tube in 2023, moving towards USD 500-650 by 2025.
Mid-term (2026-2030)
- Market Adjustment: With continued patent losses, generic versions could account for 60-70% of sales.
- Price Range for Generics: USD 300-400 per tube.
- Brand Pricing: Likely to maintain premiums of 20-25% over generics, but margins will tighten.
Long-term Trends
In the next five years, innovation in formulations (e.g., sustained-release gels or patches) may stabilize or enhance premium pricing niches. Regulatory shifts favoring biosimilar acceptance could further press prices downward.
Factors Influencing Market and Price Trajectory
- Patent Expirations: Key patents for TESTIM and competitors expire by 2022-2024, increasing generic competition.
- Regulatory Approvals: Launch of biosimilar testosterone formulations could reduce costs.
- Manufacturing Costs: Marginal reductions expected due to scale and process improvements.
- Insurance and Reimbursement Policies: Favorability impacts patient access and volume.
- Prescribing Trends: Rising awareness of TRT safety and efficacy influences demand.
What Are the Key Takeaways?
- TESTIM remains a significant player in the testosterone gel market but faces growing generic competition.
- Prices are expected to decrease by approximately 30-50% over the next five years.
- Market growth will be partly driven by demographic trends, but pricing pressures will intensify.
- The entry of biosimilars and generics will significantly influence long-term pricing and market share.
- The therapeutic landscape may evolve with innovation and regulatory changes, impacting the value landscape.
FAQs
1. When do key patents for TESTIM expire?
Most primary patents expired around 2018-2020, leading to increased generic entry.
2. How much do generic testosterone gels cost compared to TESTIM?
Generics are priced at USD 300-400 per 30-gram tube, roughly 40-50% lower than TESTIM's brand price.
3. Will TESTIM maintain a premium price in the future?
It may retain a premium of 20-25% over generics if formulations, brand loyalty, and physician preference persist.
4. How is the market expected to grow?
The testosterone therapy market is projected to grow at 4-6% CAGR globally through 2030.
5. What factors could disrupt current price trends?
Regulatory approval of biosimilar testosterone products and significant shifts in reimbursement policy could accelerate price reductions.
References
[1] MarketsandMarkets, "Testosterone Replacement Therapy Market by Product, Distribution Channel and Region," 2022.
More… ↓
